Cargando…

Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer

BACKGROUND: Osteoporosis is a skeletal disorder characterized by compromised bone strength, resulting in increased fracture risk. Patients with prostate cancer may have multiple risk factors contributing to bone fragility: advanced age, hypogonadism, and long-term use of androgen-deprivation therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussain, Arif, Tripathi, Abhishek, Pieczonka, Christopher, Cope, Diane, McNatty, Andrea, Logothetis, Christopher, Guise, Theresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134041/
https://www.ncbi.nlm.nih.gov/pubmed/33028943
http://dx.doi.org/10.1038/s41391-020-00296-y
_version_ 1783695153386487808
author Hussain, Arif
Tripathi, Abhishek
Pieczonka, Christopher
Cope, Diane
McNatty, Andrea
Logothetis, Christopher
Guise, Theresa
author_facet Hussain, Arif
Tripathi, Abhishek
Pieczonka, Christopher
Cope, Diane
McNatty, Andrea
Logothetis, Christopher
Guise, Theresa
author_sort Hussain, Arif
collection PubMed
description BACKGROUND: Osteoporosis is a skeletal disorder characterized by compromised bone strength, resulting in increased fracture risk. Patients with prostate cancer may have multiple risk factors contributing to bone fragility: advanced age, hypogonadism, and long-term use of androgen-deprivation therapy. Despite absence of metastatic disease, patients with nonmetastatic castrate-resistant prostate cancer receiving newer androgen receptor inhibitors can experience decreased bone mineral density. A systematic approach to bone health care has been hampered by a simplistic view that does not account for heterogeneity among prostate cancer patients or treatments they receive. This review aims to raise awareness in oncology and urology communities regarding the complexity of bone health, and to provide a framework for management strategies for patients with nonmetastatic castrate-resistant prostate cancer receiving androgen receptor inhibitor treatment. METHODS: We searched peer-reviewed literature on the PubMed database using key words “androgen-deprivation therapy,” “androgen receptor inhibitors,” “bone,” “bone complications,” and “nonmetastatic prostate cancer” from 2000 to present. RESULTS: We discuss how androgen inhibition affects bone health in patients with nonmetastatic castrate-resistant prostate cancer. We present data from phase 3 trials on the three approved androgen receptor inhibitors with regard to effects on bone. Finally, we present management strategies for maintenance of bone health. CONCLUSIONS: In patients with nonmetastatic castrate-resistant prostate cancer, aging, and antiandrogen therapy contribute to bone fragility. Newer androgen receptor inhibitors were associated with falls or fractures in a small subset of patients. Management guidelines include regular assessment of bone density, nutritional guidance, and use of antiresorptive bone health agents when warranted.
format Online
Article
Text
id pubmed-8134041
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-81340412021-06-01 Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer Hussain, Arif Tripathi, Abhishek Pieczonka, Christopher Cope, Diane McNatty, Andrea Logothetis, Christopher Guise, Theresa Prostate Cancer Prostatic Dis Review Article BACKGROUND: Osteoporosis is a skeletal disorder characterized by compromised bone strength, resulting in increased fracture risk. Patients with prostate cancer may have multiple risk factors contributing to bone fragility: advanced age, hypogonadism, and long-term use of androgen-deprivation therapy. Despite absence of metastatic disease, patients with nonmetastatic castrate-resistant prostate cancer receiving newer androgen receptor inhibitors can experience decreased bone mineral density. A systematic approach to bone health care has been hampered by a simplistic view that does not account for heterogeneity among prostate cancer patients or treatments they receive. This review aims to raise awareness in oncology and urology communities regarding the complexity of bone health, and to provide a framework for management strategies for patients with nonmetastatic castrate-resistant prostate cancer receiving androgen receptor inhibitor treatment. METHODS: We searched peer-reviewed literature on the PubMed database using key words “androgen-deprivation therapy,” “androgen receptor inhibitors,” “bone,” “bone complications,” and “nonmetastatic prostate cancer” from 2000 to present. RESULTS: We discuss how androgen inhibition affects bone health in patients with nonmetastatic castrate-resistant prostate cancer. We present data from phase 3 trials on the three approved androgen receptor inhibitors with regard to effects on bone. Finally, we present management strategies for maintenance of bone health. CONCLUSIONS: In patients with nonmetastatic castrate-resistant prostate cancer, aging, and antiandrogen therapy contribute to bone fragility. Newer androgen receptor inhibitors were associated with falls or fractures in a small subset of patients. Management guidelines include regular assessment of bone density, nutritional guidance, and use of antiresorptive bone health agents when warranted. Nature Publishing Group UK 2020-10-07 2021 /pmc/articles/PMC8134041/ /pubmed/33028943 http://dx.doi.org/10.1038/s41391-020-00296-y Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Hussain, Arif
Tripathi, Abhishek
Pieczonka, Christopher
Cope, Diane
McNatty, Andrea
Logothetis, Christopher
Guise, Theresa
Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
title Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
title_full Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
title_fullStr Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
title_full_unstemmed Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
title_short Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
title_sort bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134041/
https://www.ncbi.nlm.nih.gov/pubmed/33028943
http://dx.doi.org/10.1038/s41391-020-00296-y
work_keys_str_mv AT hussainarif bonehealtheffectsofandrogendeprivationtherapyandandrogenreceptorinhibitorsinpatientswithnonmetastaticcastrationresistantprostatecancer
AT tripathiabhishek bonehealtheffectsofandrogendeprivationtherapyandandrogenreceptorinhibitorsinpatientswithnonmetastaticcastrationresistantprostatecancer
AT pieczonkachristopher bonehealtheffectsofandrogendeprivationtherapyandandrogenreceptorinhibitorsinpatientswithnonmetastaticcastrationresistantprostatecancer
AT copediane bonehealtheffectsofandrogendeprivationtherapyandandrogenreceptorinhibitorsinpatientswithnonmetastaticcastrationresistantprostatecancer
AT mcnattyandrea bonehealtheffectsofandrogendeprivationtherapyandandrogenreceptorinhibitorsinpatientswithnonmetastaticcastrationresistantprostatecancer
AT logothetischristopher bonehealtheffectsofandrogendeprivationtherapyandandrogenreceptorinhibitorsinpatientswithnonmetastaticcastrationresistantprostatecancer
AT guisetheresa bonehealtheffectsofandrogendeprivationtherapyandandrogenreceptorinhibitorsinpatientswithnonmetastaticcastrationresistantprostatecancer